Terbinafine
- Generic Name
- Terbinafine
- Brand Names
- Lamisil, Silka Cream
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N
- CAS Number
- 91161-71-6
- Unique Ingredient Identifier
- G7RIW8S0XP
- Background
Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal. It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epoxidase), an enzyme that is part of the fungal cell wal...
- Indication
Terbinafine hydrochloride is indicated to treat fungal skin and nail infections caused by Trichophyton species, Microsporum canis, Epidermophyton floccosum, and Tinea species. Terbinafine hydrochloride also treats yeast infections of the skin caused by Candida species and Malassezia furfur.
- Associated Conditions
- Onychomycosis, Pityriasis versicolor, Sporotrichosis, Tinea Capitis, Tinea Corporis, Tinea Cruris, Tinea Pedis, Cutaneous candidiasis, Severe Tinea Corporis, Severe Tinea Cruris, Severe Tinea Pedis
- Associated Therapies
- -
Efficacy and Safety Study of Iontophoretic Application of Terbinafine Gel in Subjects With Onychomycosis
- Conditions
- Interventions
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2012-10-19
- Lead Sponsor
- Nitric BioTherapeutics, Inc
- Target Recruit Count
- 168
- Registration Number
- NCT01080079
- Locations
- 🇺🇸
Temple University Schoool of Podiatric Medicine, Philadelphia, Pennsylvania, United States
🇺🇸International Clinical Research, LLC, Sanford, Florida, United States
🇨🇦Lynderm Research, Inc, Markham, Ontario, Canada
Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis
- Conditions
- Interventions
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2008-06-05
- Target Recruit Count
- 56
- Registration Number
- NCT00691184
- Locations
- 🇺🇸
TKL Research Inc., Paramus, New Jersey, United States
Bioequivalency Study of Terbinafine Tablets Under Fed Conditions
- Conditions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 30
- Registration Number
- NCT00602251
- Locations
- 🇺🇸
Gateway Medical Research, Inc., Saint Charles, Missouri, United States
Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions
- Conditions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 30
- Registration Number
- NCT00602342
- Locations
- 🇺🇸
Gateway Medical Research, Inc., Saint Charles, Missouri, United States
A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 218
- Registration Number
- NCT00491764
Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail
- First Posted Date
- 2007-03-07
- Last Posted Date
- 2012-05-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 518
- Registration Number
- NCT00443898
- Locations
- 🇺🇸
Dr. Diane Baker, Lake Oswego, Oregon, United States
🇺🇸Dr. Kevin Terry, Lutherville, Maryland, United States
🇺🇸Dr. Harry Penny, Altoona, Pennsylvania, United States
Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 526
- Registration Number
- NCT00443820
- Locations
- 🇺🇸
Dr. John Mallory, Overland Park, Kansas, United States
🇺🇸Dr. Max Weisfeld, Baltimore, Maryland, United States
🇺🇸Dr. Jeffrey Conrow, Topeka, Kansas, United States
Terbinafine Compared to Griseofulvin in Children With Tinea Capitis
- Conditions
- First Posted Date
- 2005-07-08
- Last Posted Date
- 2007-02-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 720
- Registration Number
- NCT00117754
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00002394
- Locations
- 🇺🇸
Univ of Texas Med Branch, Galveston, Texas, United States
🇺🇸Hampton Roads Med Specialists, Hampton, Virginia, United States
🇺🇸Therafirst Med Ctr, Fort Lauderdale, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.